Skip to main content

Table 1 Patient characteristics at entry

From: Endoscopic sclerotherapy compared with no specific treatment for the primary prevention of bleeding from esophageal varices. A randomized controlled multicentre trial [ISRCTN03215899]

Characteristic

Sclerotherapy n = 84

Controls n = 82

Age

56(23–76)

55(20–72)

Sex (M/F) (n)

46/38

49/33

Diagnosis

  

   Alcoholic liver disease

41

40

   Hepatitis B/C

24

21

   PBC/PSC

11

8

   Other

24

31

Child-Pugh class A/B/C (n)

44/32/8

47/25/10

Child-Pugh score

6(5–12)

6(5–13)

Esophageal varices

  

   grade II

47

42

   grade III

38

40

   grade IV

15

18

Ascites

44

37

Laboratory

  

   Bilirubin (μmol/l)

27(7–429)

27(7–217)

   Albumin (g/l)

36(18–48)

35(23–47)

   AT-III (IE/l)

0.7(0.22–1.45)

0.7(0.24–1.32)

   ASAT (U/l)

44.5(12–264)

49(12–373)

  1. Results are expressed as percentages and medians with ranges, unless otherwise indicated. Normal ranges: serum bilirubin <18 μmol/l; albumin > 37 g/l; AT-III 0.85 – 1.50 IE/l; ASAT < 35 U/l